3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia
1
Interventions
Cytarabine
39
Busulfan
15
Idarubicin
14
Cyclophosphamide
13
Mitoxantrone
12
Filgrastim
12
Etoposide
12
fludarabine phosphate
11
Peripheral Blood Stem Cell Transplantation
11
Daunorubicin
9
Methotrexate
8
Cyclosporine
8
Tacrolimus
7
Whole-Body Irradiation
5
Mycophenolic Acid
5
Clofarabine
5
Cladribine
5
Biopsy
5
Azacitidine
5
Arsenic Trioxide
5
Antilymphocyte Serum
5
Radiotherapy
4
Gemtuzumab
4
Flow Cytometry
4
Decitabine
4
Cyclosporins
4
venetoclax
3
pegylated granulocyte colony-stimulating factor
3
Topotecan
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Monocytic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn